



Speed
Reliability
Value Performance

COMPUAGE INFOCOM LTD

15th July, 2022

To,
The Corporate Services Dept.
BSE Ltd.
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai 400 001.

National Stock Exchange of India Ltd.,
Exchange Plaza,
C-1, Block G, Bandra Kurla Complex,
Bandra (E),
Mumbai - 400 051.

Security Code: 532456
ISIN: INE070C01037

Symbol: COMPINFO

Sub: Compliance under Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir / Ma'am,

Pursuant to Regulation 47 of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulations, 2015, please find enclosed herewith public notice for transfer of Equity Shares of the Company to Investor Education and Protection Fund (IEPF) published in Business Standard having nationwide circulation and in Mumbai Lakshadeep having regional circulation.

You are requested to take above disclosure on record.

Thanking you,

Yours faithfully,

For Compuage Infocom Limited,

Hasti Pala

Hasti Pala
Company Secretary

Place: Mumbai
Encl: As above.



LANCET STUDY ON COVID DRUG

Glenmark nasal spray cuts viral load by 94% in 24 hrs

SOHINI DAS
Mumbai, 14 July

Glenmark's nitric oxide nasal spray (NONS), which it sells under the brand FabiSpray in India, reduces the viral load of Sars-CoV-2 in high-risk adult Covid-19 patients by 94 per cent within 24 hours and 99 per cent in 48 hours, according to the results of phase-3 trial of the drug published in *The Lancet Regional Health Southeast Asia* journal.

Glenmark had conducted the study on 306 vaccinated and unvaccinated adults with symptomatic mild Covid-19 disease across 20 clinical trial sites in India.

The trial evaluated a seven-day treatment of NONS, plus the standard of care versus placebo nasal spray and standard of care in patients.

Spike in Covid: 20k fresh cases

Daily Covid-19 cases in India were recorded over 20,000 after a gap of 145 days while the active cases increased to 1,36,076, according to the Union Health Ministry data updated on Thursday.

A total of 20,139 new Covid-19 cases were reported in a span of 24 hours, pushing the total tally of cases to 43,689,989.

The death toll climbed to 525,557 with 38 new fatalities. PTI



NONS was administered six times daily as two sprays per nostril for seven days.

"Use of NONS in patients recently infected with SARS-CoV-2 accelerates nasal virus clearance," the study published in *The Lancet* said.

It said the high-risk population (unvaccinated or over 45 years of age, or with one or more comorbidities) demonstrated a 'profound' Sars-CoV-2 RNA burden reduction of

93.7 per cent at 24 hours and 99 per cent at 48 hours with NONS.

"NONS had a rapid effect of viral RNA reduction, i.e., a 7.4 fold greater viral RNA reduction compared to placebo at 48 hours of treatment," the study showed.

Glenmark has tied up with Canadian biotech firm SaNOTize to manufacture, market, and distribute its NONS for Covid-19 treatment

in India and other Asian markets. Glenn Saldanha, managing director and chief executive of Glenmark, had told *Business Standard* last year that a major clinical trial by SaNOTize was being conducted in Canada over 4,000 people to see if the drug also works in prevention of Covid-19. It launched the nasal spray in India this February after the drug regulator gave nod to its launch after a local clinical trial.

NONS is designed to kill coronavirus in the upper airways, preventing it from incubating and spreading to the lungs.

"It is based on nitric oxide, a natural nanomolecule with proven anti-microbial properties, and which has a direct effect on SARS-CoV-2, the virus causing Covid-19," a company spokesperson has said.

NIM inclusion of anti-cancer vax may start with 9-14 yr olds

SOHINI DAS
Mumbai, 14 July

Soon, the indigenously developed human-papillomavirus (HPV) vaccine, which prevents cancer-causing infections, may be part of the National Immunisation Mission (NIM). The standing technical sub-committee of the National Technical Advisory Group on Immunisation (NTAGI) has recommended inclusion of the vaccine in the central programme.

Sources say the vaccine may be initially given to girls between the age of 9 and 14 years. "Then it can also be expanded to include boys. With an India-made vaccine now, costs will not be so much of a constraint," said a person close to the development.

Pune-based Serum Institute of India's (SII) quadrivalent HPV vaccine was approved by the country's drug regulator earlier this week. SII has not indicated the pricing yet, but said the launch will be towards



HOME-MADE VAX

- NTAGI actively considering inclusion of HPV vaccine in the NIM
- Serum Institute has not indicated the pricing yet, says will launch the vaccine by 2022-end
- NIM inclusion of HPV was held back due to high prices of foreign vaccines

the end of this calendar year. Doctors say the vaccine can be given to girls up to the age of 26 years, mostly before they become sexually active.

At the moment, two HPV vaccines available in the private market are from foreign manufacturers — Gardasil, manufactured by Merck, and Cervarix by Glaxo Smithkline. SII's entry into this space is expected to bring down the prices significantly. HPV vaccines are now available in the range of ₹2,000-3,000 per dose.

The inclusion of this vaccine in the NIM is a significant step in reducing cervical cancer burden among women.

Cervical cancer ranks as the second most frequent cancer among women in India. About 5 per cent of women in the general population are estimated to harbour cervical HPV-16/18 infection at a given time, and 83.2 per cent of invasive cervical cancers are attributed to HPV-16 or 18. HPV infection is now a well-established cause of cervical cancer and HPV types

16 and 18 are most frequent and responsible for about 70 per cent of all cervical cancer cases worldwide. India has 483.5 million women aged 15 years and older who are at risk of developing cervical cancer. Estimates indicate that every year 123,907 women are diagnosed with cervical cancer and 77,348 die from the disease.

According to the 2011 census, around 114.8 million girls were between the age of 10 and 14 years. The numbers would be slightly different now, however, one can estimate around 100-120 million female children to be in the target age group for HPV vaccination under the NIM.

Sampada Dessai, consultant, gynecologic cancer and robotic surgeon at PD Hinduja Hospital, said vaccination and screening are key tools to prevent cervical cancer. Only 12-15 per cent of the cases of HPV infection and cervical cancer are detected in early stages, as cancer remains asymptomatic in the initial stages.

Shapoorji Pallonji & Co exits Eureka, sells 8.7%

Construction major Shapoorji Pallonji and Company has exited from Eureka Forbes after selling its remaining 8.7 per cent stake to the new owner Lunolux, a firm backed by private equity firm Advent International.

Lunolux acquired 16.8 million equity shares of Eureka Forbes forming 8.7 per cent of the equity share capital of Eureka Forbes from Shapoorji Pallonji and Company on July 12, 2022, said a regulatory update by the manufacturer of the vacuum cleaner and water purifier. "Accordingly, the number of shares held by Shapoorji Pallonji and Company in Eureka Forbes Ltd has reduced from 1.68 crore to nil Equity Shares and the percentage of total share capital held by Shapoorji Pallonji and Company in Eureka Forbes Limited has been consequently diluted from 8.70 per cent to nil per cent," it said.

This is as part of the underlying transaction undertaken pursuant to the share purchase agreement dated September 19, 2021, entered between Lunolux and Shapoorji Pallonji and Co, it added. Lunolux is a special purpose vehicle incorporated by AI Global Investments (Cyprus) PCC Ltd, which operates as the investment hub for Asia for all the funds managed by Advent International.

In September last year, Advent International signed a deal to buy a majority stake in Eureka Forbes Ltd, the consumer durables flagship of the Shapoorji Pallonji Group, for ₹4,400 crore. In April, seven directors from Shapoorji Pallonji and Co resigned from the board of Eureka. PTI

Centre to states: Ensure second dose coverage of Sputnik V vax

PRESS TRUST OF INDIA
New Delhi, 14 July

The Centre has suggested states to ensure private vaccination centres providing Sputnik V vaccine reach out to beneficiaries for due doses — both second and precaution — while ensuring availability of the job.

In a letter to states and Union Territories, Union Health Secretary Rajesh Bhushan on Thursday said it has been observed that the uptake of precaution dose of Sputnik V is only 0.5 per cent of those due for it.

Stating that queries have been received by the health ministry about the precaution dose of the Russian vaccine, he referred to an e-mail to all states and Union Territories on May 5 mentioning that those who got two doses of the vaccine may be administered precaution job using Component 1 of Sputnik V in private Covid vaccination centres.

Referring to a July 6 order, Bhushan said the interval between the second and precaution doses has now been reduced to six months or 26 weeks for all vaccines.

To increase the uptake of precaution dose of Sputnik V vaccine by beneficiaries who are due for it, the health secretary urged states to ensure the availability of the Sputnik V vaccine (Component 1) and the functionality of private Covid vaccination centres.

"Private CVCs (Covid vaccination centres), which were providing Sputnik V vaccine, may reach out to due beneficiaries to receive the due doses (both second and precaution dose). Targeted communication may be established for the due beneficiaries of the precaution dose of Sputnik V. I look forward to your support so that benefit of precaution done is extended to all beneficiaries due or overdue for it," Bhushan said.



Now, all-in-one RT-PCR test for Zika, malaria

Pune-based Mylab Discovery Solutions, credited with developing India's first indigenous Sars-CoV-2 RT-PCR and the first rapid-antigen test home kit, has launched first combined RT-PCR test kit for monsoon diseases. It can differentiate between malaria, Chikungunya, dengue, Zika, Leptospirosis and Salmonellosis bacterial species, and Leishmaniasis. BS REPORTER

Syngene signs drug deal with Zoetis

Biocon arm Syngene International has signed a 10-year agreement to develop the drug substance for Librela, a monoclonal antibody used to treat osteoarthritis in dogs, with US-based animal health firm Zoetis. "This paves the way for development of other molecules and is likely to be worth up to \$500 million to Syngene over 10 years," it said. BS REPORTER

Wipro Consumer to enter packaged food biz in India

SHARLEEN D'SOUZA
Mumbai, 14 July

Wipro Consumer Care & Lighting has announced its foray into packaged food business in India. The company has appointed Anil Chugh, currently the India & SAARC head of the Wipro Consumer Care business, to head the vertical. Also, Neeraj Khatri, head of Wipro Consumer Care's Philippines entity, has moved to the role of India & SAARC head of Wipro Consumer Care business.

Vineet Agrawal, CEO of Wipro Consumer Care & Lighting, said: "Our decision to enter the packaged food business would complement our existing categories in personal care, thus building a complete offering in the FMCG space in India."

Wipro Consumer Care &

Lighting had recorded a revenue of ₹8,634 crore for the financial year ended March 31.

It operates in personal wash products, toiletries, facial care, wellness, home care, electrical wire devices, domestic and commercial lighting, and seating solutions.

"Our leadership changes align with our ambitions of being a significant and leading player in FMCG space in all the markets we operate in," said Agrawal.

The company owns popular brands such as Santoor, premium personal care brand Yardley, Enchanteur, Hygienix, Chandrika, Glucovita, Safewash, Softouch, Giffy Maxkleen along with LED lights brand Wipro Garnet and male grooming brand Aramusk.

COMPUAGE INFOCOM LIMITED
CIN: L99999MH1999PLC135914
Regd. Office: D-801/602 & G-801/602, Lotus Corporate Park, Graham Firth Steel Compound, Western Express Highway, Goregaon (East), Mumbai - 400 083.
Tel No: 022-87114444 | Fax No: 022-87114445
E-mail: investors.relations@compuageindia.com | Website: www.compuageindia.com

NOTICE FOR TRANSFER OF EQUITY SHARES OF THE COMPANY TO INVESTOR EDUCATION AND PROTECTION FUND (IEPF)

Notice is hereby given to the Shareholders of the Company pursuant to the provisions of Section 124(6) of the Companies Act, 2013 and the Investor Education and Protection Fund Authority (Accounting, Audit, Transfer and Refund) Rules, 2016, as amended from time to time.

The Rules contain provisions for transfer of all shares to Investor Education and Protection Fund (IEPF) in respect of which dividends have not been paid or claimed by the Shareholders for seven consecutive years or more.

Adhering to the set requirements, the Company has communicated individually to all concerned Shareholders whose shares are liable to be transferred to IEPF account. The unpaid or unclaimed dividend for FY 14-15 (Final Dividend) will be due for transfer to IEPF account, accordingly, the shares too.

Further, full details have been uploaded on the website of the Company at www.compuageindia.com of such Shareholders alongwith shares liable for transfer to IEPF Account.

In case, the Company does not receive any communication from the concerned Shareholders by Monday, 17th October, 2022, the Company shall, thereafter, transfer the shares to the IEPF account as per the stipulated procedure.

Shareholders may note that both unclaimed dividend and shares transferred to IEPF Account including benefits accruing on such shares, if any, can be claimed back by such Shareholder from IEPF Authority by making application in IEPF-5, as prescribed under the Rules.

In case the Shareholders have any queries on the subject matter and the Rules, they may contact Registrar and Transfer Agent, Link Intime India Pvt. Ltd., at C-101, 247 Park, L. B. S. Marg, Vikhroli (West), Mumbai-400083, Tel No.: (022) 49186270, e-mail: iepf.shares@linkintime.co.in

For Compuage Infocom Limited, Sd/-
Hasti Pala
Company Secretary

Place : Mumbai
Date : 14th July, 2022

In Loving & Respectful Memory

SHRI CHAMAN LAL SETIA
Our most revered father Shri Chaman Lal Setia
great Philanthropist and
Founder Chairman of Chaman Lal Setia Exports Ltd
passed away last year on July 15, 2021.

In Loving & Fond Memory -

Maharani Rice
Zubaan Se Dil Tak

MANAGEMENT & STAFF CHAMAN LAL SETIA EXPORTS LTD
AMRITSAR - KARNAL - GURGAON - GANDHIDHAM.

Garden Reach Shipbuilders & Engineers Ltd.
SPEARHEADING INDIGENOUS WARSHIP DESIGN & CONSTRUCTION

Launching of
The Second Warship of Project 17A (Yard 3023)
by
Hon'ble Raksha Mantri Shri Rajnath Singh
Friday, 15 Jul 2022

Builders of 100 Warships

75
आज़ादी का
अमृत महोत्सव

MAKE IN INDIA
HAR KAAM
DESH KE NAAM

Garden Reach Shipbuilders & Engineers Ltd.
(A Govt. of India Undertaking, Ministry of Defence)
61, Garden Reach Road, Kolkata-700024; E-mail: marketing@grse.co.in
Visit us at: www.grse.in
CIN No.: L 35111 WB 1934 GOI 007891

Scan the QR Code & Watch LIVE Streaming on
YouTube

Scan the QR Code to know more about GRSE

"In Pursuit of Excellence and Quality in Shipbuilding"

Follow us : [greekolkata](https://www.facebook.com/greekolkata) | [officialgrse](https://www.instagram.com/officialgrse) | [OfficialGRSE](https://www.youtube.com/OfficialGRSE) | [garden-reach-shipbuilders-&-engineers](https://www.linkedin.com/company/garden-reach-shipbuilders-&-engineers) | www.grse.in

